Nevertheless, both studies are limited to preclinical or early-phase clinical stages, and key concerns such as off-target effects, long-term safety, and heterogeneous CXCR4 expression in gliomas remain to be fully addressed. This evidence concerns the gene CXCR4 and glioma.